title: Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women.
abstract: BACKGROUND
  Increased vulnerability to mood disorders has been reported during perimenopause. Fluctuating estrogen levels accompany the perimenopausal transition. Thus, estrogen replacement therapy (ERT) has been proposed as a potentially effective treatment for mood disorders occurring during perimenopause.
  
  
  METHODS
  We examined the efficacy of ERT in the treatment of depression in 16 perimenopausal women with DSM-IV-defined major depressive disorder who were participating in the Mood Disorders Research Program at the Department of Psychiatry of the University of California, Los Angeles. Ten antidepressant- and ERT-naive women received ERT alone. Six women who were nonresponders or partial responders to an antidepressant received ERT in addition to existing treatment with fluoxetine. The Hamilton Rating Scale for Depression (HAM-D) was administered to all patients at baseline and weekly thereafter during the 8-week open-protocol trial. Partial response was operationalized as a final HAM-D score < or = 50% of the baseline score. Remission was defined as a final HAM-D score < or = 7.
  
  
  RESULTS
  All patients exhibited clinical improvement as measured by HAM-D scores after the first week of treatment. Of the 10 perimenopausal depressed women receiving ERT alone, 6 remitted, 3 partially responded to treatment, and 1 did not respond by the end of the trial. Of the 6 women receiving antidepressant treatment with ERT, 1 patient remitted and 5 had a partial response by the end of the trial.
  
  
  CONCLUSIONS
  This small study suggests that for some antidepressant-naive perimenopausal women with clinical depression, ERT may have antidepressant efficacy. In depressed women who have minimal response to a selective serotonin reuptake inhibitor, ERT may augment response. Further controlled trials are needed.
authors: Department of Psychiatry and Biobehavioral Science, University of California, Los Angeles, USA.
authors: Natalie L
authors: NL
authors: Rasgon
authors: Lori L
authors: LL
authors: Altshuler
authors: Lynn A
authors: LA
authors: Fairbanks
authors: Jennifer J
authors: JJ
authors: Dunkin
authors: Camelia
authors: C
authors: Davtyan
authors: Shana
authors: S
authors: Elman
authors: Andrea J
authors: AJ
authors: Rapkin
mesh_terms: D000328:Adult; D002979:Climacteric / Q000187:drug effects / Q000523:psychology*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D004958:Estradiol; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors